Clinical Trial Update: Hepatic Ablation of Melanoma Metastases to Enhance Immunotherapy Response, a Phase I Clinical Trial (HAMMER I) [Phase 1]

View source ↗

Summary

HAMMER I is a Phase I trial evaluating hepatic ablation of melanoma liver metastases to enhance response to immunotherapy; the study status is reported as compl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Melanoma
• Liver Metastases
• Melanoma
• Mucosal Melanoma
• Ocular Melanoma

Snippet

Sponsor: University of Michigan Rogel Cancer Center | Conditions: Melanoma, Ocular, Melanoma, Cutaneous | Phase 1 | Status: COMPLETED